Olink
Olink offers a high-multiplex technique to identify actionable biomarkers with a strong focus on the human plasma proteome. Their mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology.
Latest Content
Whitepaper
Advancing Precision Medicine in Neurology
This whitepaper provides a roadmap for leveraging advanced proteomics platforms to identify biomarkers capable of detecting disease at its earliest stages.
Infographic
The Simple Path To Proteomics in Just Nine Steps
This infographic explores a workflow that can bring proteomics to any lab in nine easy steps. Discover how to run a proteomics workflow in a short timeframe, even without prior experience.
Whitepaper
Go Beyond Genomics With NGS-Based Proteomics
This article explores how NGS-based proteomics addresses these challenges, highlights recent advancements in the field and examines its impact on multiomics research and precision medicine.
Whitepaper
Advanced Immune Monitoring To Revolutionize Vaccine Development
This interview explores expert insights into cutting-edge methodologies that overcome these challenges, providing actionable insights to optimize vaccine safety and efficacy.
Product News
Thermo Fisher Scientific Completes Acquisition of Olink
Thermo Fisher Scientific Inc. has announced that it has completed its acquisition of Olink Holding AB, a provider of next-generation proteomics solutions.
eBook
Overcome the Challenges of Multiplex Immunoassays
This eBook delves into the significance of protein biomarkers and the advancements in immunoassay techniques, from traditional ELISA to cutting-edge multiplex immunoassays.
Webinar
Population-Level Multiomics for Precision Medicine
On-Demand
Our expert speaker will explore how the findings uncover previously unknown insights into disease biology that can help accelerate the identification of new therapeutic targets and biomarkers.
Product News
New State-of-the-Art Genomic Services Facility Opening in the UK
Azenta Life Sciences has selected Oxford, UK, a key European life sciences hub, as the location for its next GENEWIZ Multiomics and Synthesis Solutions site. The site will feature a new state-of-the-art genomics lab scheduled to open in early 2024.
Whitepaper
Detect Low Abundance Biomarkers in Murine Models
In this interview, delve into the significance of measuring immune mediators with high sensitivity, revolutionizing our understanding of disease dynamics.
Webinar
Advancing Biomarker Discovery in Ovarian Cancer With High-Throughput Proteomics
On-Demand
This webinar presents a high-throughput proteomics platform used to identify proteins linked to ovarian cancer. A 22-protein model accurately distinguishes cancer cases from benign controls.
Advertisement
